Treatment with zanamivir -- an antiviral drug -- combined with celecoxib and mesalazine -- nonsteroidal anti-inflammatory agents -- reduced an overreaction of the immune system and improved the survival rates of mice injected with fatal doses of the H5N1 avian flu virus, scientists in Hong Kong found. Clinical trials of the three drugs should be conducted because the drugs might prove effective in humans and "decrease the mortality rate to 20%, theoretically," one of the researchers said.

Full Story:

Related Summaries